相关实验视频

Updated: Sep 19, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在非小细胞肺癌中ARID1A突变状态:从分子病理学到临床影响,重点关注与EGFR的关系

Claudia Di Lecce¹, Serena Eccher², Michele Simbolo³

¹Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Lung cancer (Amsterdam, Netherlands)

|June 4, 2025

概括

在ARID1A中功能丧失突变影响非小细胞肺癌 (NSCLC) 的预后和治疗. 这些变化会对表皮生长因子受体氨酸激酶抑制剂的疗效产生负面影响,但可能预测对免疫检查点抑制剂的反应更好.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

肺癌是全球癌症死亡的主要原因之一.
非小细胞肺癌 (NSCLC) 是最常见的类型,通常具有表皮生长因子受体 (EGFR) 突变.
在SWI/SNF复合体中的瘤抑制剂ARID1A在~8%的肺癌中发生突变,主要是功能丧失 (LOF).

研究的目的:

研究ARID1A LOF突变在NSCLC中的预后和预测作用.
探索ARID1A LOF影响治疗反应的分子机制.
要突出ARID1A突变在NSCLC患者结局中的双重作用.

主要方法:

在NSCLC队列中分析ARID1A突变状态.
研究受ARID1A LOF影响的分子通路,包括PI3K/AKT信号传输.
评估ARID1A LOF与对EGFR氨酸激酶抑制剂 (EGFR-TKI) 和免疫检查点抑制剂 (ICI) 的反应有关.

主要成果:

ARID1A LOF突变与NSCLC预后不佳有关.
这些突变通过PI3K/AKT激活等途径损害EGFR-TKI的有效性.
相反,ARID1A LOF突变可以预测与免疫微环境调节相关的ICI的有利反应.

结论:

在NSCLC中,ARID1A LOF突变作为双重预后和预测生物标志物.
了解这些突变对于优化NSCLC治疗策略至关重要.
需要进一步的研究,以充分阐明ARID1A突变的复杂生物学和治疗影响.

关键词:

在 ARID1A 中.染色体重塑染色体的重塑欧洲农业基金会 (EGFR) 是一个.在NSCLCLC中,我们可以看到NSCLCLC.在 SWI/SNF 中.

更多相关视频

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...